Shelley Chu, MD, PhD
Dr. Chu has two decades of venture investing and operating experience in the biopharmaceutical industry. To date, her investments have led to seven new drug approvals (NDAs) by the FDA, nine drug candidates in ongoing clinical development, and 16 exits through mergers and acquisitions, IPOs or partnerships. During her time at Gilead, she led R&D strategy across all therapeutic areas and business development in immuno-oncology and HBV. At Lightspeed, she leads the firm’s biotech investments from seed to late stage.
